Foghorn Therapeutics Inc (FHTX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Foghorn Therapeutics Inc (FHTX) has a cash flow conversion efficiency ratio of 0.205x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-22.27 Million) by net assets ($-108.50 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Foghorn Therapeutics Inc balance sheet quality to measure how much of total assets are equity-financed.
Foghorn Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Foghorn Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Foghorn Therapeutics Inc (FHTX) reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Foghorn Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Foghorn Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Asia Sermkij Leasing Public Company Limited
BK:ASK
|
0.203x |
|
Exotic Food Public Company Limited
BK:XO
|
0.107x |
|
Canada Nickel Company Inc
V:CNC
|
-0.014x |
|
Abrdn Emerging Markets Equity Income Fund Inc
NYSE MKT:AEF
|
-0.001x |
|
Camlin Fine Sciences Limited
NSE:CAMLINFINE
|
0.078x |
|
Crescendo Corporation Bhd
KLSE:6718
|
0.026x |
|
Space Asset Acquisition Corp. Class A Ordinary Shares
NASDAQ:SAAQ
|
N/A |
|
Nacity Property Service Co Ltd
SHG:603506
|
-0.085x |
Annual Cash Flow Conversion Efficiency for Foghorn Therapeutics Inc (2018–2025)
The table below shows the annual cash flow conversion efficiency of Foghorn Therapeutics Inc from 2018 to 2025. For the full company profile with market capitalisation and key ratios, see Foghorn Therapeutics Inc market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-108.50 Million | $-86.10 Million | 0.794x | -64.02% |
| 2024-12-31 | $-45.53 Million | $-100.41 Million | 2.205x | +44.14% |
| 2023-12-31 | $-77.19 Million | $-118.11 Million | 1.530x | -99.91% |
| 2022-12-31 | $112.00K | $193.61 Million | 1728.679x | +333351.39% |
| 2021-12-31 | $96.87 Million | $-50.25 Million | -0.519x | -142.38% |
| 2020-12-31 | $146.19 Million | $-31.29 Million | -0.214x | -140.65% |
| 2019-12-31 | $-88.02 Million | $-46.34 Million | 0.526x | -8.71% |
| 2018-12-31 | $-39.27 Million | $-22.65 Million | 0.577x | -- |
About Foghorn Therapeutics Inc
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is also developing therapies f… Read more